» Articles » PMID: 12070035

Involvement and Functional Impairment of the CD34(+)CD38(-)Thy-1(+) Hematopoietic Stem Cell Pool in Myelodysplastic Syndromes with Trisomy 8

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2002 Jun 19
PMID 12070035
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Clonality studies of mature cells suggest that the primary transformation event in myelodysplastic syndrome (MDS) most frequently occurs in a myeloid-restricted progenitor, a hypothesis supported by recent studies of purified CD34(+)Thy1(+) hematopoietic stem cells (HSCs) in cases with trisomy 8 (+8). In contrast, we recently demonstrated that a lymphomyeloid HSC is the target for transformation in MDS cases with del(5q), potentially reflecting heterogeneity within MDS. However, since +8 is known to frequently be a late event in the MDS transformation process, it remained a possibility that CD34(+)CD38(-)Thy1(+) HSC disomic for chromosome 8 might be part of the MDS clone. In the present studies, although a variable fraction of CD34(+)CD38(-)Thy1(+) cells were disomic for chromosome 8, they did not possess normal HSC activity in long-term cultures and nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice. Mixing experiments with normal CD34(+)CD38(-) cells suggested that this HSC deficiency was intrinsic and not mediated by indirect mechanisms. Furthermore, investigation of 4 MDS cases with combined del(5q) and +8 demonstrated that the +8 aberration was always secondary to del(5q). Whereas del(5q) invariably occurs in CD34(+)CD38(-)Thy-1(+) HSCs, the secondary +8 event might frequently arise in progeny of MDS HSCs. Thus, CD34(+)CD38(-)Thy1(+) HSCs are invariably part of the MDS clone also in +8 patients, and little HSC activity can be recovered from the CD34(+) CD38(-)Thy1(+) HSC. Finally, in advanced cases of MDS, the MDS reconstituting activity is exclusively derived from the minor CD34(+)CD38(-) HSC population, demonstrating that MDS stem cells have a similar phenotype as normal HSCs, potentially complicating the development of autologous transplantation for MDS.

Citing Articles

Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management.

Das M, Teli P, Vaidya A, Kale V Regen Med. 2024; 19(7-8):407-419.

PMID: 39058408 PMC: 11370962. DOI: 10.1080/17460751.2024.2378627.


Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression.

van Spronsen M, Hanekamp D, Westers T, van Gils N, Vermue E, Rutten A Leukemia. 2023; 37(3):680-690.

PMID: 36792658 PMC: 9991914. DOI: 10.1038/s41375-023-01811-5.


The Mesenchymal Niche in Myelodysplastic Syndromes.

Friedrich C, Kosmider O Diagnostics (Basel). 2022; 12(7).

PMID: 35885544 PMC: 9320414. DOI: 10.3390/diagnostics12071639.


Stem Cells in the Myelodysplastic Syndromes.

Zhan D, Park C Front Aging. 2022; 2:719010.

PMID: 35822030 PMC: 9261372. DOI: 10.3389/fragi.2021.719010.


The Coming of Age of Preclinical Models of MDS.

Liu W, Teodorescu P, Halene S, Ghiaur G Front Oncol. 2022; 12:815037.

PMID: 35372085 PMC: 8966105. DOI: 10.3389/fonc.2022.815037.